CC BY 4.0 · Journal of Coloproctology 2024; 44(S 01): S1-S138
DOI: 10.1055/s-0045-1808882
Doenças Anorretais
Anorectal Diseases
ID – 138198
Open Topics (oral presentation)

COMPLEX PERIANAL FISTULA COMPLICATED BY RECTOVAGINAL FISTULA TREATED WITH MESENCHYMAL CELLS

Barbara Andrade Prais
1   Universidade Professor Edson Antônio Velano , Belo Horizonte, Brasil
,
Carolina Vieira de Faria
2   Faculdade de Ciências Médicas e da Saúde, Juiz de Fora, Brasil
,
João Victor de Abreu Martins
3   Universidade Federal de São João del-Rei, São João del-Rei, Brasil
,
Maria Vitória Figueiredo Martins
2   Faculdade de Ciências Médicas e da Saúde, Juiz de Fora, Brasil
,
Priscila Tocantins Tanure
4   Universidade Federal de Juiz de Fora, Juiz de Fora, Brasil
,
João Baptista de Paula Fraga
4   Universidade Federal de Juiz de Fora, Juiz de Fora, Brasil
,
Rómmel Ribeiro Lourenço Costa
4   Universidade Federal de Juiz de Fora, Juiz de Fora, Brasil
,
Jander Bairral Vasconcelos
4   Universidade Federal de Juiz de Fora, Juiz de Fora, Brasil
› Institutsangaben
 

    Case Presentation A 44-year-old female patient with a history of complex perianal and rectovaginal fistula was initially diagnosed in December 2021 with a perianal abscess, which required drainage under anesthesia. In May 2022, an MRI revealed a complex perianal fistula complicated by a rectovaginal fistula, though no external opening was observed at the time. In December 2023, the patient presented with an external fistula opening, confirmed by a new MRI performed in September 2023, which aligned with physical examination findings of the fistulous tract. Treatment was initiated in January 2024 using autologous mesenchymal cells, which were collected, processed, and applied during the same procedure. At the 10-day follow-up, the patient exhibited a small amount of secretion, which was considered a normal postoperative finding. At the 120-day follow-up, anoscopy findings were normal. After 150 days, a follow-up MRI showed fibrotic scar tissue with no evidence of fistulas.

    Discussion Rectovaginal fistulas are rare conditions that occur primarily after gynecological or obstetric trauma and in the context of Crohn's disease. Other potential causes include neoplasms, pelvic radiotherapy, infections, and unintentional consequences of anorectal surgery. Treatment options for rectovaginal fistulas vary based on symptoms, fistula anatomy, adjacent tissue quality, and prior repair attempts. Mesenchymal cells, a subtype of adult stem cells, exhibit properties such as immunomodulatory, anti-inflammatory, analgesic, anti-apoptotic, and particularly neoangiogenic effects. These properties make them a promising option for treating complex perineal fistulas.

    Conclusion The use of mesenchymal cells in the treatment of complex perineal fistulas has shown promising results, as demonstrated in reported studies and in this case report.


    #

    Die Autoren geben an, dass kein Interessenkonflikt besteht.

    Publikationsverlauf

    Artikel online veröffentlicht:
    25. April 2025

    © 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution 4.0 International License, permitting copying and reproduction so long as the original work is given appropriate credit (https://creativecommons.org/licenses/by/4.0/)

    Thieme Revinter Publicações Ltda.
    Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil